Vyome Holdings (HIND)

• Market cap: $15.4M
• 1 day: -4.78%
• 5 days: 1.86%
• 1 month: -15.77%
• 3 months: -32.2%
• 6 months: -56.8%
• Year to date: -38.31%
• 1 year: -96.13%
• 5 years: -100%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.

Employees: 18